PDLIM3 Antibody

What applications are most suitable for PDLIM3 antibody detection?

PDLIM3 antibodies have been validated for multiple applications, with Western blot (WB), immunohistochemistry (IHC), and immunofluorescence/immunocytochemistry (IF/ICC) being the most commonly used. Each application requires specific optimization:

The application should be selected based on your research question. For cellular localization studies, IF/ICC provides spatial information. For quantitative expression analysis, WB offers better quantification potential, while IHC is optimal for analyzing tissue distribution patterns and correlation with pathological parameters .

What positive control tissues are recommended for validating PDLIM3 antibodies?

Selecting appropriate control tissues is critical for antibody validation. Based on established expression patterns, the following tissues are recommended:

Human Protein Atlas data confirms high expression in skeletal muscle with moderate expression in gastric tumors and negative staining in normal gastric tissues . Always include both positive and low-expressing tissues when validating a new antibody to confirm specificity and sensitivity .

What is the optimal antigen retrieval method for PDLIM3 immunohistochemistry?

Heat-induced epitope retrieval (HIER) is essential for optimal PDLIM3 detection in FFPE tissues. The following methods have proven effective:

The effectiveness of antigen retrieval may vary depending on the specific epitope targeted by the antibody. In immunohistochemistry studies of gastric cancer tissues, researchers successfully detected PDLIM3 using these retrieval methods, achieving clear cytoplasmic staining visible under light microscopy . Always optimize retrieval conditions for your specific tissue and fixation protocol.

How can I validate the specificity of a PDLIM3 antibody?

Comprehensive antibody validation requires multiple complementary approaches:

• Molecular weight verification: Confirm band size at 35-39 kDa (calculated MW is 39kDa, observed MW is typically 35-39kDa) in Western blot

• Comparison with mRNA expression data: Correlate antibody staining with transcriptional data from databases like GEO or from qPCR analysis of the same samples

• Knockdown/knockout validation: Test antibody on samples where PDLIM3 has been deleted via CRISPR or silenced via RNAi

• Cross-antibody validation: Compare results using antibodies targeting different PDLIM3 epitopes (e.g., PDZ domain vs. LIM domain)

• Peptide competition assay: Pre-incubate antibody with immunizing peptide to block specific binding

• Tissue panel validation: Test across tissues with known differential expression (high in muscle, low in cerebral cortex)

Multiple validation methods should be employed to ensure antibody specificity before proceeding to complex experimental applications .

What are the recommended storage conditions for maintaining PDLIM3 antibody activity?

Proper storage is critical for maintaining antibody performance over time:

Most commercial PDLIM3 antibodies come in glycerol-containing buffers that prevent freeze-thaw damage. Aliquoting upon receipt is recommended to avoid repeated freeze-thaw cycles that can degrade antibody performance .

How can PDLIM3 antibodies be used to investigate its role in SHH pathway activation in medulloblastoma?

PDLIM3 has been identified as a key supporter of hedgehog signaling in medulloblastoma, particularly in the SHH subgroup. To investigate this relationship:

• Subgroup expression analysis: Use PDLIM3 antibodies to compare expression across medulloblastoma subgroups (WNT, SHH, Group 3, Group 4). Research shows significantly higher expression in SHH-MB compared to other subgroups (p < 0.001)

• SHH signaling correlation: Perform dual immunostaining for PDLIM3 and GLI1 (a key SHH pathway effector). Studies demonstrated that PDLIM3 deletion significantly reduced GLI1 protein levels in medulloblastoma cells

• Cilia localization studies: Employ immunofluorescence to co-localize PDLIM3 with primary cilia markers. Research has confirmed PDLIM3 localization to primary cilia in MB cells, mediated by its PDZ domain

• Domain function analysis: Use domain-specific antibodies alongside PDLIM3 mutant constructs (full-length, PDZ-only, LIM-only) to determine which domains are essential for SHH pathway regulation. Studies showed the PDZ domain is critical for cilia localization and function

• Functional pathway assessment: Combine PDLIM3 antibody staining with CRISPR-mediated knockout followed by SHH pathway readouts. Research confirmed that PDLIM3 deletion significantly compromised cilia formation and interfered with Hh signaling transduction in MB cells

Implementation of these approaches has revealed that PDLIM3 promotes Hh signaling by supporting ciliogenesis through cholesterol provision, highlighting its potential as a molecular marker for defining SHH group of MB in clinical settings .

What are the considerations when using PDLIM3 antibodies to study immune cell infiltration in gastric cancer?

PDLIM3 expression in gastric cancer has been linked to immune cell infiltration patterns, presenting unique considerations for immunological studies:

• Correlation with immune cell markers: PDLIM3 expression shows significant positive correlation with infiltration of specific immune cell populations:

  Immune Cell Type	Correlation Coefficient	p-value	Implications
  Macrophages	0.671	6.39e−51	Strongest correlation
  Myeloid dendritic cells	0.38	1.69e−14	Moderate correlation
  CD4+ T cells	0.355	1.11e−12	Moderate correlation
  CD8+ T cells	0.346	4.30e−12	Moderate correlation
  Neutrophils	0.307	9.73e−10	Moderate correlation
  B cells	0.037	4.77e−1	Weak/no correlation

• Multiplex immunostaining protocols: When designing multiplex panels including PDLIM3:

  • Select antibodies raised in different species to avoid cross-reactivity

  • Include sequential staining steps when using multiple rabbit antibodies

  • Use tyramide signal amplification for weak signals

  • Include appropriate spectral unmixing controls

• Tumor microenvironment assessment: PDLIM3 expression correlates with extracellular matrix formation and leukocyte transendothelial migration according to GO and KEGG analyses

• Prognostic correlation analysis: When studying PDLIM3 in relation to immune infiltration, stratify analysis by clinical parameters (staging, Her-2 overexpression, differentiation grade, Lauren classification) to reveal subgroup-specific patterns

• Signaling pathway integration: Include markers for PI3K/Akt signaling pathway, which shows enrichment in PDLIM3-related genes in gastric cancer

These approaches have revealed that upregulation of PDLIM3 is significantly associated with immune cell infiltration in gastric cancer, potentially serving as a biomarker to predict prognosis and immune cell infiltration patterns .

How can I optimize co-immunoprecipitation protocols using PDLIM3 antibodies to identify novel interaction partners?

Co-immunoprecipitation (Co-IP) with PDLIM3 antibodies requires careful optimization:

• Antibody selection: Choose antibodies validated for immunoprecipitation applications with minimal cross-reactivity. Polyclonal antibodies often perform better for Co-IP due to recognition of multiple epitopes

• Lysis buffer optimization:

  Buffer Component	Recommended Concentration	Rationale
  Tris-HCl pH 7.4-8.0	20-50 mM	Maintains physiological pH
  NaCl	100-150 mM	Physiological ionic strength
  NP-40 or Triton X-100	0.5-1%	Mild detergent preserves interactions
  Glycerol	5-10%	Stabilizes protein structure
  Protease inhibitors	As recommended	Prevents degradation
  Phosphatase inhibitors	As recommended	Preserves phosphorylation

• Cross-linking considerations: For studying PDLIM3's interaction with cholesterol, consider using photoactivatable cholesterol analogs with UV cross-linking to capture transient interactions

• Specific controls:

  • IgG control from same species as PDLIM3 antibody

  • Input control (5-10% of lysate)

  • PDLIM3 knockout/knockdown negative control

  • Reverse Co-IP verification of key interactions

• Domain-specific interactions: Consider using domain-specific antibodies or domain deletion mutants to map interaction domains. Research has demonstrated that the PDZ domain mediates cilia localization and certain protein interactions

• Validation of interactions: Confirm interactions using alternative methods such as proximity ligation assay, FRET, or domain-specific pull-downs

This approach has successfully identified PDLIM3's interaction with cholesterol, which proved critical for its function in ciliogenesis and hedgehog signaling in medulloblastoma .

What strategies can be employed to distinguish between different PDLIM3 isoforms using antibodies?

PDLIM3 exists in multiple isoforms with tissue-specific expression patterns. To distinguish between them:

• Isoform-specific expression patterns:

  Isoform	Primary Expression	Molecular Weight	Distinguishing Features
  Isoform 1	Skeletal muscle	~39 kDa	Highly expressed in differentiated skeletal muscle
  Isoform 2	Heart	~35 kDa	Heart-specific expression
  Isoform 3	Various	Variable	Less characterized

• Epitope mapping strategy: Select antibodies targeting regions unique to specific isoforms:

  • N-terminal antibodies may detect all isoforms

  • Antibodies against splice junction-specific sequences can be isoform-specific

  • Use peptide competition with isoform-specific peptides to confirm specificity

• Resolution techniques:

  • High-resolution SDS-PAGE with gradient gels (e.g., 8-16%) can separate isoforms with small size differences

  • 2D electrophoresis can resolve isoforms with similar sizes but different post-translational modifications

  • Combine with mass spectrometry for definitive isoform identification

• RT-PCR correlation: Validate protein detection with RT-PCR using isoform-specific primers to confirm expression patterns

• Tissue-specific controls: Use heart tissue (isoform 2-predominant) and skeletal muscle (isoform 1-predominant) as biological controls for isoform specificity

Understanding isoform-specific expression is critical when interpreting PDLIM3 antibody results across different tissue types or disease states .

How can PDLIM3 antibodies be utilized in studying the protein's role in ciliogenesis and cholesterol interaction?

PDLIM3's newly discovered role in ciliogenesis presents unique opportunities for antibody-based investigations:

• Cilia co-localization studies:

  • Use co-immunofluorescence with PDLIM3 antibodies and cilia markers (acetylated α-tubulin, ARL13B)

  • Optimize fixation methods to preserve delicate ciliary structures (4% PFA, 10-15 minutes)

  • Consider super-resolution microscopy for precise subcellular localization

• Domain-specific localization:

  • Research demonstrated that the PDZ domain of PDLIM3 is critical for cilia localization

  • Compare staining patterns of antibodies targeting different domains (PDZ vs. LIM)

  • Correlate with expression of domain deletion constructs (FL▵PDZ showed compromised cilia localization)

• Cholesterol interaction studies:

  • PDLIM3 physically interacts with cholesterol, crucial for cilia formation

  • Use filipin staining alongside PDLIM3 immunofluorescence to visualize cholesterol

  • Consider cholesterol depletion/addition experiments to assess impact on PDLIM3 localization

• Quantitative analysis of cilia parameters:

  • Measure cilia length and frequency in cells with varied PDLIM3 expression

  • Research showed PDLIM3-null cells had significantly reduced cilia formation and length

  • Restoration of PDLIM3 expression rescued cilia defects

• Rescue experiments:

  • Treatment with exogenous cholesterol significantly rescued cilia formation and Hh signaling in PDLIM3-null cells

  • Use PDLIM3 antibodies to track protein localization before and after cholesterol supplementation

These approaches have revealed that PDLIM3 facilitates ciliogenesis through cholesterol provision, establishing a mechanistic link between PDLIM3, cilia formation, and Hedgehog signaling pathway activation .

What are common issues with PDLIM3 antibodies in Western blots and how can they be resolved?

Western blot troubleshooting for PDLIM3 detection requires systematic optimization:

Research observations indicate that PDLIM3 typically appears at 35-39 kDa on Western blots, with some variation between tissue types. Heart tissue often shows predominance of the 35 kDa isoform, while skeletal muscle shows the 39 kDa isoform .

How can I improve PDLIM3 detection in immunohistochemistry of difficult tissues?

Optimizing IHC for challenging tissue samples requires attention to multiple parameters:

• Fixation optimization:

  • Limit fixation time to 24-48 hours for optimal epitope preservation

  • Consider alternative fixatives for sensitive epitopes (zinc-based fixatives)

• Enhanced antigen retrieval:

  • Extend HIER time to 25-30 minutes for heavily fixed tissues

  • Try dual pH retrieval (sequential pH 6 and pH 9 retrieval)

  • Consider enzymatic retrieval as an alternative approach

• Signal amplification options:

  • Tyramide signal amplification (TSA) can enhance sensitivity 10-50 fold

  • Polymer-based detection systems improve signal without background

  • Consider biotin-free detection systems to reduce background

• Background reduction:

  • Include avidin/biotin blocking for tissues with endogenous biotin

  • Use species-specific blocking sera matched to host species of secondary antibody

  • Consider tissue-specific blocking (e.g., milk for mammary tissues)

• Quantification strategies:

  • Use average integral optical density (IOD) measurements for objective quantification

  • Research successfully used IOD to measure PDLIM3 immunostaining in gastric tumors (41.7 ± 16.5) compared to matched normal tissues (19.5 ± 10.8)

These optimizations have enabled successful PDLIM3 detection even in tissues with variable expression levels, allowing for accurate comparison between normal and pathological samples .

What controls are essential when studying PDLIM3 in knockout/knockdown experiments?

Rigorous experimental design for PDLIM3 genetic manipulation studies requires comprehensive controls:

• Validation controls:

  • Verify knockout/knockdown efficiency using both antibodies and mRNA analysis

  • Confirm specificity by testing multiple PDLIM3 antibodies targeting different epitopes

  • Include wild-type cells/tissues as positive controls

• Functional controls:

  • Rescue experiments using full-length PDLIM3 to confirm phenotype specificity

  • Domain-specific rescue (PDZ-only vs. FL▵PDZ) to map functional regions

  • Research demonstrated that PDZ domain alone restored cilia formation in PDLIM3-null cells

• Pathway validation controls:

  • Measure GLI1 protein levels as readout of Hedgehog pathway activity

  • Compare SHH-stimulated vs. unstimulated conditions

  • Research showed PDLIM3 deletion inhibited GLI1 upregulation after SHH treatment

• In vivo validation:

  • In transplantation studies, include both mCherry-control and PDLIM3-gRNA cells

  • Monitor both proliferation (Ki67) and differentiation (NeuN) markers

  • PDLIM3-null tumor cells showed significantly reduced proliferation and increased differentiation in vivo

• Cholesterol rescue experiments:

  • Include cholesterol supplementation conditions to test mechanism specificity

  • Exogenous cholesterol significantly rescued cilia formation and Hh signaling in PDLIM3-null cells

These control strategies have enabled researchers to definitively establish PDLIM3's role in Hedgehog signaling, ciliogenesis, and tumor cell proliferation .

How can PDLIM3 antibodies be used to investigate the relationship between PDLIM3 and PI3K/Akt signaling pathways?

PDLIM3 has been linked to PI3K/Akt signaling in gastric cancer, presenting opportunities for mechanistic investigation:

These approaches can help elucidate whether PDLIM3 acts upstream, downstream, or as a co-regulator of the PI3K/Akt pathway in cancer contexts .

What are the best practices for quantifying PDLIM3 expression levels in comparative tissue studies?

Accurate quantification of PDLIM3 expression across sample types requires standardized approaches:

• Western blot quantification:

  • Use gradient gels (8-16%) for optimal resolution of PDLIM3 isoforms

  • Include loading controls appropriate for your experimental context (β-actin may be inappropriate if studying cytoskeletal changes)

  • Employ digital image acquisition with linear dynamic range

  • Use densitometry software with background subtraction capabilities

• IHC scoring methods:

  • Measure average integral optical density (IOD) of staining in multiple fields (minimum 5 random fields at ×200 magnification)

  • Consider automated digital pathology approaches for unbiased quantification

  • Use standardized scoring systems (H-score, Allred score) for semi-quantitative analysis

  • Include internal reference standards on each slide for normalization

• RNA-protein correlation:

  • Validate protein expression patterns with mRNA analysis from the same samples

  • Research demonstrated concordance between protein and mRNA expression in gastric cancer samples

• Statistical analysis recommendations:

  • For paired tumor-normal comparisons, use paired statistical tests

  • For multiple group comparisons (e.g., cancer subtypes), use ANOVA with appropriate post-hoc tests

  • Include survival analysis stratified by PDLIM3 expression levels

• Sample preparation standardization:

  • Standardize fixation time and conditions across all samples

  • Process all samples simultaneously when possible to minimize batch effects

  • Include technical replicates to assess method variability

Implementation of these quantification practices enabled researchers to objectively demonstrate that PDLIM3 immunostaining in gastric tumors (41.7 ± 16.5) was significantly stronger than in matched non-tumor samples (19.5 ± 10.8) (p < 0.05) .